OrthoPediatrics sees FY26 revenue $262M-$266M, consensus $263.07M

OrthoPediatrics (KIDS) projects 2026 revenue to be in the range of $262M to $266M, representing 11% to 13% growth compared to full year 2025 preliminary unaudited net revenue. The Company also expects approximately $10M annual set deployment and expects to generate approximately $25M Adjusted EBITDA in 2026. “Throughout 2025, we delivered another year of strong performance, advanced our strategic initiatives, and widened our leadership position in pediatric orthopedics. Our Trauma and Deformity and Scoliosis implant businesses continued to execute effectively, taking market share, driving topline revenue, and improving profitability,” commented David Bailey, President & CEO of OrthoPediatrics. “We are also extremely pleased with the specialty bracing business, which remains a tremendous market opportunity and a strategic catalyst for deepening customer relationships. OPSB is proving to be a capital-efficient driver of both revenue and earnings, and we are only beginning to unlock its full potential as we scale in the years ahead. In 2025, we helped over 37,500 children in the fourth quarter alone and nearly 1.3 million since inception, while generating record preliminary unaudited revenue growth of 15% from 2024, and significantly reducing free cash flow usage year-over-year. Looking forward, we are confident that our growth drivers and operational discipline position us to execute on our long-term outlook and continue making a meaningful impact for children worldwide.”